Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

Older adults with subjective memory loss are more likely to develop dementia

A new study published in the January 11, 2010 issue of the journal Alzheimer's and Dementia, finds that symptoms of cognitive decline can be experienced some 20 years before an Alzheimer's diagnosis.

13 Jan 2010

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

A study published in the January 13, 2010 issue of the Journal of Neuroscience links a loss of smell function in Alzheimer's disease (AD) model animals with amyloid β (protein) accumulation in the brain, a distinguishing hallmark of Alzheimer's disease. Research conducted by NYU Langone Medical Center suggests that olfactory dysfunction, a common symptom of AD, may serve as an early diagnostic tool for the disease.

13 Jan 2010

Scientists identify fast-acting compound to improve cognitive function impairments

A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery.

13 Jan 2010

Research suggests variation of CETP gene is linked to lowered risk of dementia and AD

Preliminary research suggests that variation of a gene for a plasma protein is associated with slower age-related memory decline and a lower risk of dementia and Alzheimer disease (AD), according to a study in the January 13 issue of JAMA.

13 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.

12 Jan 2010

Prescribing culture of antipsychotic medications in nursing homes examined

Older adults newly admitted to nursing homes with high rates of antipsychotic prescribing in the previous year are more likely to receive antipsychotic agents, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Of these treated patients, some had no identified clinical indication for this therapy.

12 Jan 2010

Abe's Garden raises $3.5M to include a facility to care for adults with Alzheimer's disease

Abe's Garden, a non-profit organization that seeks to establish a national model of residential living and daycare programs for those suffering with Alzheimer's disease, has raised $3.5 million toward its $9 million capital campaign announced today.

12 Jan 2010

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference.

12 Jan 2010

DSG teams up with pharmaceutical technology company to speed early detection of major diseases

DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical technology company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.

12 Jan 2010

Experiments show Alzheimer's drug may halt the growth of oesophageal cancer

Cancer of the gullet, or oesophagus, is one of the ten most common cancers in the Western world, and there have been recent alarming increases in the number of cases each year in the US and UK.

12 Jan 2010

Cognitively stimulating activities are beneficial, but mental exercises help some more than others

If you don't have a college degree, you're at greater risk of developing memory problems or even Alzheimer's. Education plays a key role in lifelong memory performance and risk for dementia, and it's well documented that those with a college degree possess a cognitive advantage over their less educated counterparts in middle and old age.

12 Jan 2010

University of Haifa receives grant to investigate role of protein expression in memory formation

Prof. Kobi Rosenblum, Head of the Department of Neurobiology and Ethology at the University of Haifa, has been awarded a -1.6 million grant from DIP, a German-Israeli Project Cooperation, over a five-year period. This grant will fund Prof. Rosenblum's international research of the role of protein expression in memory formation and stability.

12 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

New technique may help researchers to test amyloid hypothesis in AD development

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD.

11 Jan 2010

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts – from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO.

9 Jan 2010

UCF research opens a new exploratory path for Alzheimer's disease

Despite a massive global research effort, many basics of Alzheimer's disease onset remain elusive. This has hampered development of treatments effective during the earliest stages of the disease, when prevention is most likely.

9 Jan 2010

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

John C. Lechleiter, PhD, Chairman, President & CEO, Eli Lilly and Company, will deliver a keynote address, "Lifespans and Livelihoods: The Human Dimensions of Medical Innovation," to TOWN HALL Los Angeles on Thursday, January 14, 2010 at the Millennium Biltmore Hotel.

8 Jan 2010

Subjective cognitive impairment in healthy older adults can increase risk for dementia

Forgot where you put your car keys? Having trouble recalling your colleague's name? If so, this may be a symptom of subjective cognitive impairment (SCI), the earliest sign of cognitive decline marked by situations such as when a person recognizes they can't remember a name like they used to or where they recently placed important objects the way they used to.

8 Jan 2010

Alzheimer's Disease News and Research

Further Reading

New findings may yield novel therapies for chronic neurodegenerative diseases

Older adults with subjective memory loss are more likely to develop dementia

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

Scientists identify fast-acting compound to improve cognitive function impairments

Research suggests variation of CETP gene is linked to lowered risk of dementia and AD

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Prescribing culture of antipsychotic medications in nursing homes examined

Abe's Garden raises $3.5M to include a facility to care for adults with Alzheimer's disease

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

DSG teams up with pharmaceutical technology company to speed early detection of major diseases

Experiments show Alzheimer's drug may halt the growth of oesophageal cancer

Cognitively stimulating activities are beneficial, but mental exercises help some more than others

University of Haifa receives grant to investigate role of protein expression in memory formation

Targacept signs collaboration and license agreement with AstraZeneca

New technique may help researchers to test amyloid hypothesis in AD development

Selection of therapeutic workshops to be presented at the Twelfth Annual BIO CEO & Investor Conference

UCF research opens a new exploratory path for Alzheimer's disease

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

Subjective cognitive impairment in healthy older adults can increase risk for dementia

Aneuro: A Year of Neuroscience in Review eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News